What are the key differences in management of MAS vs RDS when surfactant therapy is considered?

What are the key differences in management of MAS vs RDS when surfactant therapy is considered?

• A. MAS may require more extensive airway management and ventilation; surfactant can be used if there is underlying surfactant deficiency; treat MAS with oxygen and ventilation.
• B. RDS never uses surfactant therapy.
• C. MAS is treated by surfactant only, with no supportive care.
• D. Surfactant administration is contraindicated in MAS.

Answer: (A)

Managing MAS differs from RDS because MAS involves airway obstruction and chemical irritation from meconium, which creates patchy lung areas and often requires more aggressive airway management. In contrast, RDS is primarily caused by a deficiency of surfactant, so surfactant therapy is a central, routine treatment. In MAS, surfactant therapy can be beneficial if there is concomitant surfactant deficiency or significant alveolar collapse, but it is not the sole approach; the main stays are ensuring adequate oxygenation and ventilation, and addressing the airway problem through careful suctioning, possible bronchoscopy, and lung-protective ventilation strategies. This combination—potential surfactant use when indicated, plus oxygen and ventilation support and thorough airway management—best captures the management approach for MAS compared with RDS. RDS routinely relies on surfactant therapy as a primary intervention, while MAS is not treated by surfactant alone. Surfactant administration is not contraindicated in MAS, and treating MAS involves more than surfactant alone, including airway clearance and supportive care.

Managing MAS differs from RDS because MAS involves airway obstruction and chemical irritation from meconium, which creates patchy lung areas and often requires more aggressive airway management. In contrast, RDS is primarily caused by a deficiency of surfactant, so surfactant therapy is a central, routine treatment. In MAS, surfactant therapy can be beneficial if there is concomitant surfactant deficiency or significant alveolar collapse, but it is not the sole approach; the main stays are ensuring adequate oxygenation and ventilation, and addressing the airway problem through careful suctioning, possible bronchoscopy, and lung-protective ventilation strategies. This combination—potential surfactant use when indicated, plus oxygen and ventilation support and thorough airway management—best captures the management approach for MAS compared with RDS.

RDS routinely relies on surfactant therapy as a primary intervention, while MAS is not treated by surfactant alone. Surfactant administration is not contraindicated in MAS, and treating MAS involves more than surfactant alone, including airway clearance and supportive care.